Immunotech Laboratories Stock

Immunotech Laboratories EBIT

The EBIT of Immunotech Laboratories (IMMB) as of Aug 16, 2026 is -958,935.00 USD.

EBIT

-958,935.00USD

Last updated:

In 2026, Immunotech Laboratories's EBIT was -958,935.00 USD, a % increase from the - USD EBIT recorded in the previous year.

The Immunotech Laboratories EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2000
0.00 base
Jan 1, 2001
0.00 base
Jan 1, 2002
0.00 base
Jan 1, 2003
0.00 base
Jan 1, 2004
0.00 base
Jan 1, 2005
0.00 base
Jan 1, 2009
0.00 base
YEAREBIT (undefined USD)
2009 -
2005 -
2004 -
2003 -
2002 -
2001 -
2000 -
Access this data via the Eulerpool API

Immunotech Laboratories Revenue

Immunotech Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2000
0.00 USD
-300,000.00 USD
-315,000.00 USD
Jan 1, 2001
0.00 USD
-723,000.00 USD
-753,000.00 USD
Jan 1, 2002
0.00 USD
-886,000.00 USD
-1.55 M USD
Jan 1, 2003
22,000.00 USD
-587,000.00 USD
-615,000.00 USD
Jan 1, 2004
0.00 USD
-107,000.00 USD
-111,000.00 USD
Jan 1, 2005
0.00 USD
-2.03 M USD
-33.60 M USD
Jan 1, 2009
0.00 USD
-958,935.00 USD
-977,570.00 USD

Immunotech Laboratories Margins

Immunotech Laboratories stock margins

The Immunotech Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunotech Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunotech Laboratories.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2000
0.00 %
- %
- %
Jan 1, 2001
0.00 %
- %
- %
Jan 1, 2002
0.00 %
- %
- %
Jan 1, 2003
0.00 %
-2,668.18 %
-2,795.45 %
Jan 1, 2004
0.00 %
- %
- %
Jan 1, 2005
0.00 %
- %
- %
Jan 1, 2009
0.00 %
- %
- %

Immunotech Laboratories Stock analysis

What does Immunotech Laboratories do? Immunotech Laboratories Inc is a biotechnology company specializing in the development and marketing of immunotherapies for the treatment of various diseases. The company was founded in 2005 in California, USA. Immunotech Laboratories focuses on the development of immunotherapies for diseases such as HIV/AIDS, Hepatitis C, cancer, and autoimmune diseases. The business model of Immunotech Laboratories is based on the development of innovative immunotherapies using natural compounds. The company collaborates closely with leading scientists and experts in the field of immunology. The developed therapies undergo various clinical trials and are commercially distributed upon successful approval. Immunotech Laboratories specializes in different areas in order to offer a wide range of therapies to its customers. For example, the company develops immunotherapies for the treatment of HIV/AIDS. Immunotech Laboratories combines different compounds to reduce viral load in the body and aid the immune system in fighting the infection. Another important area for Immunotech Laboratories is the development of immunotherapies for cancer treatment. The company utilizes innovative approaches that enable the body's natural defenses to recognize and combat cancer cells. Combination of different compounds is also employed to enhance effectiveness. In addition to these areas, Immunotech Laboratories also offers immunotherapies for the treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company employs innovative approaches that enable the immune system to recognize and fight pathogens causing these diseases. Immunotech Laboratories offers a range of products developed based on immunotherapies. These include different combinations of compounds for the treatment of HIV/AIDS and Hepatitis C, as well as immunotherapies for cancer and autoimmune diseases. These products are available in the form of injections, capsules, or tablets and can be prescribed by physicians. Overall, Immunotech Laboratories is an innovative biotechnology company specializing in the development and marketing of immunotherapies. The company collaborates with leading experts in immunology and develops innovative approaches for the treatment of various diseases. The offered products are known for their high effectiveness and tolerability, helping patients worldwide improve their health. Immunotech Laboratories is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Immunotech Laboratories's EBIT

Immunotech Laboratories's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immunotech Laboratories's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immunotech Laboratories's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immunotech Laboratories’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immunotech Laboratories stock

EBIT of Immunotech Laboratories is -958,935.00 USD in 2026.

On Eulerpool you can find the complete historical development of EBIT Immunotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Immunotech Laboratories historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Immunotech Laboratories

All Key Metrics — Immunotech Laboratories